Drug Profile
Research programme: overactive bladder therapies - Urigen
Alternative Names: URG 300 programme; URG 302Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Urigen Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Overactive bladder
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Overactive bladder in USA (Transurethral, Suppository)
- 24 Aug 2007 Preclinical trials in Overactive bladder in USA (Transurethral)